You are here

  • Home
  • Archive
  • Volume 30, Issue Suppl 3
  • 16 Quality-adjusted (QA) progression-free survival analyses of veliparib + carboplatin/paclitaxel (CP) vs CP alone in patients with newly diagnosed ovarian cancer

Citation Tools

Article menu

Download PDFPDF

Oral Plenary
Plenary V
IGCS20_1101
16 Quality-adjusted (QA) progression-free survival analyses of veliparib + carboplatin/paclitaxel (CP) vs CP alone in patients with newly diagnosed ovarian cancer
Free

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Alvarez Secord A, Bookman M, Coleman R, et al
16 Quality-adjusted (QA) progression-free survival analyses of veliparib + carboplatin/paclitaxel (CP) vs CP alone in patients with newly diagnosed ovarian cancer
International Journal of Gynecologic Cancer 2020;30:A12.